| Assay ID | Title | Year | Journal | Article |
|---|
| AID1386958 | Thermodynamic solubility in pH 7.4 buffer | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386966 | Agonist activity at human V1b receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386885 | Displacement of [tyrosyl-2,6-3H] oxytocin from OTR (unknown origin) expressed in HEK293 cell membranes incubated for 60 mins | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386884 | Displacement of [3H]-vasopressin from V1A receptor (unknown origin) expressed in HEK293 cell membranes incubated for 60 mins | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1493739 | Displacement of [3H]-vasopressin from human vasopressin V1a receptor expressed in HEK293 cell membranes after 90 mins by radioligand binding assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. |
| AID1476737 | Selectivity ratio of Ki for vasopressin V1b receptor (unknown origin) to Ki for recombinant mouse OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1386963 | Agonist activity at mouse OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to OT | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1476740 | Selectivity ratio of EC50 for vasopressin V1b receptor (unknown origin) to EC50 for recombinant human OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1386934 | Antagonist activity at human OTR expressed in HEK cells assessed as inhibition of OT-induced intracellular calcium flux at 1 uM incubated for 45 mins by Indo1-AM dye based fluorescence assay relative to OT | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1277200 | Binding affinity to vasopressin 1a receptor (unknown origin) | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1386960 | Agonist activity at human OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386962 | Agonist activity at mouse OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1493742 | Antagonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as inhibition of vasopressin-induced IP1 accumulation preincubated for 30 mins followed by vasopressin addition measured after 1 hr by HTRF assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. |
| AID1476739 | Selectivity ratio of EC50 for vasopressin V2 receptor (unknown origin) to EC50 for recombinant human OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1277186 | Antagonist activity at human oxytocin receptor expressed in HEK293 cells assessed as inhibition of oxytocin induced IP1 accumulation pretreated for 30 mins measured 1 hr post Ab-Cryptate and IP1-d2 addition by HTRF assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1277199 | Agonist activity at recombinant human oxytocin receptor expressed in CHO-DUKX-A2 cells assessed as change in intracellular calcium level by FLIPR assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1386985 | Agonist activity at recombinant human OTR expressed in CHO-DUKX-A2 cells assessed as stimulation of intracellular calcium concentration by calcium 3 dye based FLIPR assay relative to OT | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386879 | Displacement of [Tyrosyl-2,6-3H]oxytocin from recombinant human OTR expressed in CHO-DUKX-A2 cells incubated for 180 mins by scintillation counting based whole cell radioligand binding assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1277188 | Agonist activity at human vasopressin 1a receptor expressed in HEK293 cells assessed as increase in IP1 accumulation preincubated for 1 hr followed by addition of Ab-Cryptate and IP1-d2 by HTRF assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1386975 | Agonist activity at human OTR receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1476736 | Selectivity ratio of Ki for vasopressin V2 receptor (unknown origin) to Ki for recombinant mouse OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1476733 | Agonist activity at recombinant mouse OTR expressed in CHO-K1 cells assessed as induction of Ca2+ mobilization after overnight incubation by FLIPR assay | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1277194 | Selectivity ratio of EC50 for vasopressin 1a receptor (unknown origin) to EC50 for oxytocin receptor (unknown origin) | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1277185 | Agonist activity at human oxytocin receptor expressed in HEK293 cells assessed as increase in IP1 accumulation preincubated for 1 hr followed by addition of Ab-Cryptate and IP1-d2 by HTRF assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1450445 | Agonist activity at C-terminal GFP-tagged OTR (unknown origin) expressed in HEK293 cells measured after 18 hrs by luciferase reporter gene assay | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
| Potent and selective oxytocin receptor agonists without disulfide bridges. |
| AID1493740 | Agonist activity at human OTR expressed in HEK293 cells assessed as induction of IP1 accumulation after 1 hr by HTRF assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. |
| AID1386881 | Binding affinity to V1A receptor (unknown origin) | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386880 | Agonist activity at recombinant human OTR expressed in CHO-DUKX-A2 cells assessed as stimulation of intracellular calcium concentration by calcium 3 dye based FLIPR assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1476734 | Selectivity ratio of Ki for vasopressin V1a receptor (unknown origin) to Ki for recombinant human OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1476735 | Selectivity ratio of Ki for vasopressin V1a receptor (unknown origin) to Ki for recombinant mouse OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1386977 | Agonist activity at human V1a receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386964 | Agonist activity at human V1a receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1277184 | Displacement of [3H]-oxytocin from human oxytocin receptor expressed in HEK293 cells after 90 mins by microbeta 2 microplate reader analysis | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1386978 | Agonist activity at human V1b receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1476732 | Agonist activity at recombinant human OTR expressed in CHO-K1 cells assessed as induction of Ca2+ mobilization after overnight incubation by FLIPR assay | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1476727 | Displacement of [Tyrosyl-2,6-3H]Oxytocin from recombinant human OTR expressed in CHO-DUKX-A2 cells after 180 mins by liquid scintillation counting method | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1277192 | Selectivity ratio of Ki for vasopressin 2 receptor (unknown origin) to Ki for oxytocin receptor (unknown origin) | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1277191 | Selectivity ratio of Ki for vasopressin 1a receptor (unknown origin) to Ki for oxytocin receptor (unknown origin) | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1386961 | Agonist activity at human OTR receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to OT | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1493741 | Agonist activity at human vasopressin V1a receptor expressed in HEK293 cells assessed as induction of IP1 accumulation after 1 hr by HTRF assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. |
| AID1277189 | Antagonist activity at human vasopressin 1a receptor expressed in HEK293 cells assessed as inhibition of vasopressin induced IP1 accumulation pretreated for 30 mins measured 1 hr post Ab-Cryptate and IP1-d2 addition by HTRF assay | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1386882 | Binding affinity to V1B receptor (unknown origin) | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386974 | Agonist activity at human V2 receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1493738 | Displacement of [3H]-oxytocin from human OTR expressed in HEK293 cell membranes after 90 mins by radioligand binding assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. |
| AID1386926 | Displacement of DY647 from SNAP-tagged V2 receptor (unknown origin) expressed in HEK293 cells by TR-FRET assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1476731 | Displacement of [Tyrosyl-2,6-3H]Oxytocin from recombinant mouse OTR expressed in CHO-K1 cells after 180 mins by liquid scintillation counting method | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1277196 | Selectivity ratio of EC50 for vasopressin 1b receptor (unknown origin) to EC50 for oxytocin receptor (unknown origin) | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1386986 | Agonist activity at human OTR stably expressed in HEK cells by calcium flux assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386927 | Agonist activity at human V2 receptor expressed in HEK cells assessed as increase in intracellular calcium flux incubated for 45 mins by Indo1-AM dye based fluorescence assay relative to AVP | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386924 | Agonist activity at human V1A receptor expressed in HEK cells assessed as increase in intracellular calcium flux at 1 uM incubated for 45 mins by Indo1-AM dye based fluorescence assay relative to AVP | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1277197 | Selectivity ratio of Ki for human oxytocin receptor expressed in HEK293 cells to Ki for human vasopressin 1a receptor expressed in HEK293 cells | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1277190 | Ratio of Ki for human oxytocin receptor expressed in HEK293 cells to Ki for recombinant human oxytocin receptor expressed in CHO-DUKX-A2 cells | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1476738 | Selectivity ratio of EC50 for vasopressin V1a receptor (unknown origin) to EC50 for recombinant human OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1386969 | Agonist activity at human V2 receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay relative to AVP | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386929 | Displacement of DY647 from SNAP-tagged OTR receptor (unknown origin) expressed in HEK293 cells by TR-FRET assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1476728 | Selectivity ratio of Ki for vasopressin V1b receptor (unknown origin) to Ki for recombinant human OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1386923 | Displacement of DY647 from SNAP-tagged V1A receptor (unknown origin) expressed in HEK293 cells by TR-FRET assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386976 | Agonist activity at human OTR receptor expressed in HEK293FT cells incubated for 30 mins by beta-arrestin recruitment assay relative to OT | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386928 | Antagonist activity at human V2 receptor expressed in HEK cells assessed as inhibition of AVP-induced intracellular calcium flux incubated for 45 mins by Indo1-AM dye based fluorescence assay relative to AVP | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1476741 | Selectivity ratio of EC50 for vasopressin V1a receptor (unknown origin) to EC50 for recombinant mouse OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1277198 | Displacement of [Tyrosyl-2,6-3H]-Oxytocin from recombinant human oxytocin receptor expressed in CHO-DUKX-A2 cells after 180 mins by liquid scintillation counting analysis | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1386925 | Antagonist activity at human V1A receptor expressed in HEK cells assessed as inhibition of AVP-induced intracellular calcium flux incubated for 45 mins by Indo1-AM dye based fluorescence assay relative to AVP | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386932 | Agonist activity at human OTR expressed in HEK cells assessed as increase in intracellular calcium flux incubated for 45 mins by Indo1-AM dye based fluorescence assay relative to OT | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1277187 | Displacement of [3H]-vasopressin from human vasopressin 1a receptor expressed in HEK293 cells after 90 mins by microbeta 2 microplate-reader method | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1386883 | Binding affinity to V2 receptor (unknown origin) | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386930 | Agonist activity at human OTR expressed in HEK cells assessed as increase in intracellular calcium flux incubated for 45 mins by Indo1-AM dye based fluorescence assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1386968 | Agonist activity at human V2 receptor expressed in HEK293FT cells assessed as stimulation of calcium release by Aequorin based assay | 2018 | Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
| LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. |
| AID1476742 | Selectivity ratio of EC50 for vasopressin V2 receptor (unknown origin) to EC50 for recombinant mouse OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1476743 | Selectivity ratio of EC50 for vasopressin V1b receptor (unknown origin) to EC50 for recombinant mouse OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1277193 | Selectivity ratio of Ki for vasopressin 1b receptor (unknown origin) to Ki for oxytocin receptor (unknown origin) | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1277195 | Selectivity ratio of EC50 for vasopressin 2 receptor (unknown origin) to EC50 for oxytocin receptor (unknown origin) | 2016 | European journal of medicinal chemistry, Jan-27, Volume: 108 | Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. |
| AID1476729 | Selectivity ratio of Ki for vasopressin V2 receptor (unknown origin) to Ki for recombinant human OTR | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
| Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |